Vigil Neuroscience Inc - Asset Resilience Ratio
Vigil Neuroscience Inc (VIGL) has an Asset Resilience Ratio of 29.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Vigil Neuroscience Inc (VIGL) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Vigil Neuroscience Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vigil Neuroscience Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Vigil Neuroscience Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VIGL liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $25.77 Million | 29.72% |
| Total Liquid Assets | $25.77 Million | 29.72% |
Asset Resilience Insights
- Very High Liquidity: Vigil Neuroscience Inc maintains exceptional liquid asset reserves at 29.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vigil Neuroscience Inc Industry Peers by Asset Resilience Ratio
Compare Vigil Neuroscience Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Vigil Neuroscience Inc (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Vigil Neuroscience Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.94% | $58.78 Million | $117.69 Million | +3.12pp |
| 2023-12-31 | 46.82% | $65.95 Million | $140.86 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $200.39 Million | -- |
About Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more